Release Date: December 22, 2025

Expiration Date: December 22, 2026

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in the field of schizophrenia. In this educational program, these experts discuss the rationale for muscarinic receptor modulation, clinical data, and the use of xanomeline/trospium chloride, the recently approved therapy in this class for the management of schizophrenia.

This educational activity is an archive of the live symposium held on November 22, 2025.

Target Audience

This educational activity is directed toward psychiatrists who treat patients with a range of psychiatric disorders. Psychiatric nurse practitioners, psychiatric nurses, pharmacists, and other health care professionals interested in the treatment of patients with psychiatric disorders are invited to participate.

Learning Objectives

Upon completion of this activity, participants will be able to:

Identify the role of the cholinergic pathway in the pathophysiology of schizophrenia
Assess clinical trial data for agents targeting muscarinic receptors for schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

GET STARTED WITH THIS PROGRAM:

Create Account Already Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.25 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Bristol Myers Squibb.

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

GET STARTED WITH THIS PROGRAM:

Related Content